How much funding has DurVena raised?

DurVena has disclosed $14M raised across 1 round.

Where is DurVena headquartered?

DurVena is headquartered in Mission, US.

DurVena

Mission, US · Delaware corporation

DurVena is commercializing a photochemical tissue passivation (PTP) therapy that strengthens harvested saphenous vein grafts to improve long-term patency in coronary artery bypass graft (CABG) procedures. Its PTP System, which has received FDA Breakthrough Device Designation, reinforces venous tissue to reduce graft expansion, intimal hyperplasia, and failure rates.

BiotechHealthtechMedical Devices

Founders & leadership

Eric SchloteExecutive

Board

Robert ThatcherBoard director

William AustenBoard director

Reported raises · per SEC filings

Form D private placements

$14M disclosed across 1 round · 2024

▶$14MraisedJan 2025 · 37 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Robert ThatcherDirector
Eric SchloteExecutive Officer, Director
William AustenDirector

Offering amount: $16.2M
Amount sold: $14M
First sale: Dec 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Intervene Inc3 shared keywordsInterVene, Inc. is a medical device company that has developed a fully integrated mechanical thrombectomy system to treat venous in-stent restenosis and residual thrombotic venous obstructions and occlusions. Its technology targets venous disease conditions such as postthrombotic syndrome that current therapies fail to address.

Companies competing with DurVena for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does DurVena do?: DurVena is commercializing a photochemical tissue passivation (PTP) therapy that strengthens harvested saphenous vein grafts to improve long-term patency in coronary artery bypass graft (CABG) procedures. Its PTP System, which has received FDA Breakthrough Device Designation, reinforces venous tissue to reduce graft expansion, intimal hyperplasia, and failure rates.
How much funding has DurVena raised?: DurVena has disclosed $14M raised across 1 round.
Where is DurVena headquartered?: DurVena is headquartered in Mission, US.